Topics
Low-grade gliomas | Treatment | Targeted therapy | Dabrafenib
Home > Publications > Topics > Low-grade gliomas > Treatment > Targeted terapy > Dabrafenib
2024
Dar MS, Shahid N, Waqas A, Baig YA,
Khan AW.
Dabrafenib
plus Trametinib: A breakthrough in pediatric low-grade glioma
therapy.
Health
Sci Rep. 2024 Jan
25;7(1):e1841. doi:
10.1002/hsr2.1841. PMID:
38274133. Interventional
study. ˍ
2025
Campino GA, Shrot S, Constantini S, Roth J, Toren A, Lurye M,
Yalon-Oren M.
Significant clinical and
radiologic response to targeted therapy in pediatric
cervicomedullary low-grade gliomas harboring the BRAFV600E
mutation.
Childs
Nerv Syst. 2025 Dec 21;41(1):429. doi:
10.1007/s00381-025-07084-w. PMID:
41423525. Case report. ˍ
2026
Figueira K, Pigott LE.
Outcomes of
target therapies for pediatric BRAF V600-mutant low-grade gliomas:
A systematic review and meta-analysis.
Neurooncol
Adv. 2026 Jul 27;8(1):vdag192. doi:
10.1093/noajnl/vdag192. PMID:
42633479. ˍ